Introduction Newer antiepileptic drugs (AEDs) are increasingly prescribed; however, relatively limited data are available regarding their use in status epilepticus (SE) and the impact on outcome. Objectives The aim of this study was to explore the evolution in prescription patterns of newer and traditional AEDs in this clinical setting, and their association with prognosis. Methods We analyzed our prospective adult SE registry over a 10-year period (2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016) and assessed the yearly use of newer and traditional AEDs and their association with mortality, return to baseline conditions at discharge, and SE refractoriness, defined as treatment resistance to two AEDs, including benzodiazepines. Results In 884 SE episodes, corresponding to 719 patients, the prescription of at least one newer AED increased from 0.38 per SE episode in 2007 to 1.24 per SE episode in 2016 (mostly due to the introduction of levetiracetam and lacosamide). Traditional AEDs (excluding benzodiazepines) decreased over time from 0.74 in 2007 to 0.41 in 2016, correlating with the decreasing use of phenytoin. The prescription of newer AEDs was independently associated with a lower chance of return to baseline conditions at discharge (odds ratio [OR] 0.58, 95% confidence interval [CI] 0.40-0.84) and a higher rate of SE refractoriness (OR 19.84,), but not with changes in mortality (OR 1.08, 95% CI 0.58-2.00). Conclusion We observed a growing trend in the prescription of newer AEDs in SE over the last decade; however, our findings might suggest an associated increased risk of SE refractoriness and new disability at hospital discharge. Pending prospective, comparative studies, this may justify some caution in the routine use of newer AEDs in SE.
Introduction
Status epilepticus (SE) represents one of the most frequent neurological emergencies, with significant morbidity and mortality. It thus requires prompt treatment in order to avoid cerebral damage, systemic complications, or death [1, 2] . Current SE treatment recommendations are based on a three-step approach, with benzodiazepines as first-line treatment, followed by intravenous antiepileptic drugs (AEDs). If SE termination is not achieved despite the first two lines of therapy, general anesthesia and coma induction may be necessary [1] [2] [3] [4] .
AEDs are a heterogeneous group of medications with a variety of pharmacokinetic and pharmacodynamic effects. Over the past 2 decades, a rapid expansion in the number and type of AEDs has been witnessed, including several with intravenous formulations. AEDs are commonly divided into newer and traditional AEDs, according to the year of marketing (before or after 1990). In the treatment of epilepsy, newer compounds generally exhibit better tolerability and lower drug interaction, with comparable efficacy to traditional AEDs [5] . Accordingly, a growing trend in the use of newer AEDs is being reported, although indications other than epilepsy seem to also contribute [6] [7] [8] [9] [10] .
Several studies have already analyzed the efficacy of newer AEDs in SE [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ; however, besides a previous preliminary analysis by our group [20] , little is known regarding the evolution over time of AED prescription patterns in SE and its impact on clinical outcome. The aims of this study were to explore the changes in the prescription of newer and traditional AEDs in SE treatment over the last decade, and their association with prognosis.
Methods
In this cohort study, we retrospectively analyzed our prospective SE registry recording data on adults with SE episodes treated in our hospital, details of which have been described elsewhere [21, 22] . Briefly, SE was defined as continuous or repetitive seizures, without full recovery in between, lasting more than 30 min (until 2008) and more that 5 min (since 2008) [23] . All patients were identified by the neurological consulting team and the staff of the epilepsy/electroencephalogram (EEG) unit. Children under 16 years of age and subjects with post-anoxic SE were not included. The SE treatment guidelines from our hospital recommend a slow bolus of intravenous clonazepam 0.015 mg/kg, midazolam 0.15 mg/kg (which can also be administered intramuscularly), or lorazepam 0.1 mg/kg as first-line therapy, and intravenous levetiracetam 30 mg/kg, valproate 30 mg/kg, or phenytoin 20 mg/kg, as second-line therapy.
We retrieved data of SE episodes between 1 January 2007 (the first entire year after commencement of the registry) and 31 December 2016, a period encompassing the introduction in Switzerland of several newer intravenous AEDs, such as levetiracetam (2008) and lacosamide (2009). These data included demographics, etiology defined as 'potentially fatal' if potentially leading to death independently of SE treatment [24] , the validated Status Epilepticus Severity Score (STESS; relying on age, history of seizures, seizure type, and extent of consciousness impairment prior to treatment) [25] , type and number of AEDs prescribed, coma induction for SE treatment, SE refractoriness (defined as the need for more than two treatment lines), and outcome at hospital discharge. The latter was categorized as return to baseline clinical conditions, new handicap, or death [21] .
AEDs were divided into two groups according to the year of marketing (before or after 1990): benzodiazepines, phenobarbital, phenytoin, valproic acid, and carbamazepine were considered 'traditional AEDs', while levetiracetam, pregabalin, gabapentin, lamotrigine, lacosamide, topiramate, felbamate, retigabine, oxcarbazepine, rufinamide, perampanel and brivaracetam (used off-label in our hospital at the end of 2016 as it was not introduced in Switzerland until January 2017) were considered 'newer AEDs'. Propofol, thiopental, corticosteroids, ketamine, etomidate, ketogenic diet, emergency surgery, or lack of treatment (spontaneous resolution of the SE episode) were considered separately.
Evolution of the use of both traditional AEDs (including and excluding benzodiazepines, which alone represent the first treatment line and were thus supposed to be consistently prescribed over time) and newer AEDs was reported as the yearly ratio between the total number of prescribed AEDs belonging to a given group (traditional versus newer) and the number of SE events. Of note, more than one newer or traditional AED could be used in a given episode. The frequency of the prescription of individual AEDs were then reported as a percentage of the SE episodes for each year.
Statistical analysis was performed using Stata version 14 (StataCorp LP, College Station, TX, USA). To test associations with clinical outcome, univariable analyses over the whole study period were performed using the Student's t test and Chi-square test, as needed. Stepwise multivariable logistic regressions were used to identify variables independently associated with mortality (considering patients and not episodes), return to baseline condition, and refractory SE. Goodness of fit was assessed using the Hosmer-Lemeshow test.
Results
We recorded 884 SE episodes during the 10-year study period, corresponding to 719 patients. Clinical characteristics are shown in Table 1 . The yearly incidence of SE markedly increased during the studied time lapse (from 58 episodes in 2007 to 86 episodes in 2016), while the proportions of patients with a history of previous seizures or potentially fatal etiologies, as well as the proportion of SE semiological types (data not shown), remained globally stable.
Over the entire study period, traditional AEDs were prescribed 1382 times and newer AEDs 767 times. As shown in Fig. 1 , the frequency of use of newer AEDs gradually increased, whereas the utilization of traditional AEDs remained stable over time as a whole, but decreased if benzodiazepines were excluded. Globally, the prescription of at least one newer AED increased from 0. The frequency of use of individual AEDs, used in at least 10% of episodes in 1 year, is shown in Fig. 2 . Among traditional AEDs, phenytoin showed the most obvious decrease, while the prescription of valproate remained relatively constant. Phenobarbital and carbamazepine were used very rarely (used indeed, respectively, 17 and 8 times). The prescription pattern of benzodiazepines also showed some evolution; clonazepam was most frequently and constantly administered. Lorazepam, diazepam, clobazam and oxazepam were not commonly administered, and their frequency of use decreased slightly. However, the use of midazolam as a first-line agent increased from 0% in 2007 to 15% in 2016, and, as a third-line compound, from 0% in 2007 to 9% in 2016.
Among newer AEDs, levetiracetam and lacosamide showed a major increase in use. In 2007, levetiracetam was used in only 30% of SE episodes, but from 2010, 2 years after the introduction of its intravenous formulation in Switzerland, it was prescribed in more than 50% of SE episodes. Intravenous lacosamide was introduced in Switzerland in 2009, together with the oral form, and, since Further therapeutic approaches, such as thiopental (12 cases), corticosteroids (14 cases), ketamine (6 cases), ketogenic diet (3 cases), surgery (2 cases), and etomidate (1 case) remained extremely rare over the study period. Finally, one to four patients per year did not receive any treatment as their SE episode resolved spontaneously.
The number of refractory SE cases gradually increased through time (Fig. 3) , with an average of 2.17 ± 1.98 AEDs prescribed per SE in 2007 and 2.98 ± 1.5 AEDs prescribed in 2016. The mean STESS score slightly increased from 2.5 ± 1.2 in 2007 to 2.7 ± 1.5 in 2016. The need for intubation also increased; in 2007, 10% of patients were treated with pharmacological coma for SE treatment, whereas in 2016 this approach was used in 22% of SE episodes. Outcome at discharge tended to evolve towards a smaller proportion of return to baseline clinical conditions; mortality remained stable (Fig. 4) .
In univariate analyses, potentially fatal etiology, higher STESS score, intubation for SE treatment, SE refractoriness to the first two treatment lines, and newer AED prescriptions correlated with poorer prognosis, whereas higher STESS score, potentially fatal etiology, and newer AEDs were associated with refractory SE. Table 2 illustrates the results of univariable and multivariable analyses, adjusted for recognized outcome predictors, especially SE severity (STESS) and etiology. The prescription of newer AEDs was independently correlated to a higher proportion of disabilities at discharge and a higher rate of treatment failures, but not with increased mortality. These three models showed acceptable goodness of fit (p = 0.33 
Discussion
During the 10 years under study, the overall prescription of newer AEDs showed an important increase that was inversely correlated to that of traditional AEDs (excluding benzodiazepines). While mortality at hospital discharge did not change significantly, the use of newer AEDs was independently associated with higher SE refractoriness and disability at discharge. A similar trend of increasing prescriptions of newer compounds has already been described, not only in SE but also more generally in patients with epilepsy and in the general population [6] [7] [8] [9] [10] 20] . In the present study, this increase was mainly due to the introduction of levetiracetam and lacosamide. Only 2 years after the marketing of intravenous levetiracetam in Switzerland, it became the most frequently used AED in SE in our center, after benzodiazepines. This abrupt rise could, at least in part, be explained by the previous existence of the oral form; physicians may have already been familiar with this agent, generating a shorter adaptation time. Lacosamide became the second most frequently prescribed AED since 2015, 4 years after its marketing.
Regarding traditional AEDs, changes in the prescription of phenytoin mostly accounted for the observed reduction, whereas utilization of valproate remained globally stable. The potential side effects of phenytoin, together with the relatively difficult clinical administration (implying cardiac monitoring) and clinical follow-up (difficult pharmacokinetics and challenging hepatic interactions), could explain its decrease to the benefit of newer compounds with better tolerability, easier administration, and supposed similar efficacy [17, 26] .
Prescription of newer AEDs was associated with higher disability at hospital discharge after adjustment for SE severity assessed through the STESS score, SE etiology, intubation for SE treatment, and, importantly, SE refractoriness. This result differs from previous assessments suggesting a comparable efficacy of newer compounds in patients with epilepsy [17, 19, [27] [28] [29] [30] . In those studies, the vast majority of patients had generalized convulsive SE, thus possibly limiting generalizability to patients, such as in the present cohort, including all SE types. A previous study from our group, restricted to the years 2006-2010, reported similar findings as compared with the present study [20] , with a greater likelihood of receiving newer AEDs in patients with more aggressive forms of SE (stratified by potentially fatal etiology, higher STESS, or refractory SE). Indeed, as newer AEDs present fewer cardiorespiratory side effects, a low potential for interactions, and linear pharmacokinetic properties, they could be prescribed preferentially in patients with comedications and significant comorbidities ('confounding by indication'). Nevertheless, our multivariable analysis was adjusted for important outcome predictors, including SE and etiology severities, total number of prescribed AEDs, and SE refractoriness.
Finally, the number of SE episodes in our center almost doubled between 2007 and 2016, possibly due to the increase in EEG monitoring in the last years [31] and the detection of more aggressive SE forms in patients with altered consciousness [32] . Of note, the breakdown into the different SE semiological types did not change significantly between 2007 and 2016. Nevertheless, patients treated with newer AEDs showed a higher rate of refractoriness, even after correction for STESS score and etiology, which could suggest a lower efficacy of newer compounds. A potential explanation could be that newer AEDs can be administered faster than phenytoin, thus shortening the time during which the clinical response is assessed. This, in turn, might induce clinicians to consider treatment escalation quicker than previously. However, the increase in the proportion of patients with a new disability at discharge seems to contradict this possibility. In line with this consideration, a recent randomized controlled trial did not disclose any benefit regarding generalized convulsive SE control after the addition of levetiracetam to clonazepam [33] .
Levetiracetam was by far the most frequently used newer AED. Various studies, including a meta-analysis, comparing levetiracetam with phenytoin or valproate, showed no difference in terms of clinical seizure cessation [17, 19] ; however, analysis from our group described a higher rate of treatment failures with levetiracetam than valproate [18] . This may reflect a suboptimal SE treatment approach with insufficient doses of newer AEDs, or prescriptions with or without underdosed benzodiazepines as first-line treatment [34] . However, in animal studies, levetiracetam has shown a relatively slow penetration into the central nervous system, with latencies of more than 1 h to achieve maximum concentrations in the cerebrospinal or brain extracerebral fluid [35] [36] [37] . On the other hand, animal studies with phenytoin show maximum concentrations in cerebrospinal and brain extracerebral fluids within 9-13 min and 39-34 min, respectively [38] . This could possibly correlate with a slower clinical action of levetiracetam and at least partially explain the relationship between refractoriness and newer AEDs.
To the best of our knowledge, our study is the first to analyze prescription patterns of AEDs in SE over a long time period in a large, well-characterized, adult cohort. With the SE registry being prospectively filled by the same investigators, its internal validity appears robust. Nevertheless, we acknowledge limitations. We assessed only the prescription of AEDs, without information relating to treatment side effects. Furthermore, we aimed to describe the evolution trends of AED use in the era of newer compounds, but not at analyzing the impact of each single medication. A selection bias may be present, as we considered only patients from a university hospital; however, in our country, the vast majority of SE patients are treated in larger hospitals. Due to retrospective data analysis, some confounding factors might have been at play. We used multivariable analyses to adjust for the most important known outcome predictors; however, the adequacy of firstline treatment, adherence to guidelines, and SE duration were not assessed. Nevertheless, a previous study from our group reported no major effect of treatment adherence to guidelines on prognosis after consideration of robust outcome predictors (etiology, STESS score) over a more restricted time lapse [39] . It also seems unlikely that the poorer outcome found in patients treated with newer AEDs could be explained by a systematic difference in treatment appropriateness between the two groups. Outcome was scored at hospital discharge; an information bias may have been at play regarding newer disabilities, which evolve over time. While a systematic bias seems unlikely, we underscore that mortality, being a robust variable, did not correlate with newer AED prescriptions. In any case, these considerations do not apply to SE refractoriness. The definition of SE timing changed in 2008; however, we extrapolate that this may have led us to miss, at most, only seven episodes lasting less than 30 min in 2007 (corresponding to less than 1% of the total number). Finally, due to the study design, the described associations do not necessarily reflect causality.
Conclusion
A growing trend in newer AED prescriptions in SE has been observed over the last decade. However, our findings do not show a resulting improvement in prognosis, but rather they seem to suggest an association with increased new disabilities at discharge, as well as SE refractoriness. These findings are potentially concerning and call for some caution in the indiscriminate use of newer AEDs in SE. The ongoing ESETT trial [40] may help in elucidating this issue.
